DK3012255T3 - Stabil krystalform af tipiracilhydrochlorid og krystalliseringsfremgangsmåde dertil - Google Patents
Stabil krystalform af tipiracilhydrochlorid og krystalliseringsfremgangsmåde dertil Download PDFInfo
- Publication number
- DK3012255T3 DK3012255T3 DK14814354.8T DK14814354T DK3012255T3 DK 3012255 T3 DK3012255 T3 DK 3012255T3 DK 14814354 T DK14814354 T DK 14814354T DK 3012255 T3 DK3012255 T3 DK 3012255T3
- Authority
- DK
- Denmark
- Prior art keywords
- tipiracilhydrochloride
- crystal form
- stable crystal
- crystallization procedure
- crystallization
- Prior art date
Links
- 238000002425 crystallisation Methods 0.000 title 1
- 230000008025 crystallization Effects 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- KGHYQYACJRXCAT-UHFFFAOYSA-N tipiracil hydrochloride Chemical compound Cl.N1C(=O)NC(=O)C(Cl)=C1CN1C(=N)CCC1 KGHYQYACJRXCAT-UHFFFAOYSA-N 0.000 title 1
- 229960001740 tipiracil hydrochloride Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013126567 | 2013-06-17 | ||
| PCT/JP2014/065985 WO2014203877A1 (ja) | 2013-06-17 | 2014-06-17 | チピラシル塩酸塩の安定形結晶及びその結晶化方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3012255T3 true DK3012255T3 (da) | 2021-12-06 |
Family
ID=52104609
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK14814354.8T DK3012255T3 (da) | 2013-06-17 | 2014-06-17 | Stabil krystalform af tipiracilhydrochlorid og krystalliseringsfremgangsmåde dertil |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US9527833B2 (da) |
| EP (2) | EP3012255B1 (da) |
| JP (2) | JP6364409B2 (da) |
| KR (1) | KR101806346B1 (da) |
| CN (4) | CN104395307A (da) |
| AU (2) | AU2014282281C1 (da) |
| BR (1) | BR112015031619B1 (da) |
| CA (2) | CA2985006C (da) |
| CY (1) | CY1124868T1 (da) |
| DK (1) | DK3012255T3 (da) |
| ES (1) | ES2898408T3 (da) |
| GE (2) | GEP20186875B (da) |
| HK (1) | HK1203071A1 (da) |
| HR (1) | HRP20211903T1 (da) |
| HU (1) | HUE057352T2 (da) |
| LT (1) | LT3012255T (da) |
| MA (1) | MA38668B2 (da) |
| MX (1) | MX2015016986A (da) |
| MY (1) | MY173410A (da) |
| NZ (1) | NZ714090A (da) |
| PH (1) | PH12015502809A1 (da) |
| PL (1) | PL3012255T3 (da) |
| PT (1) | PT3012255T (da) |
| RS (1) | RS62691B1 (da) |
| RU (2) | RU2674441C1 (da) |
| SG (4) | SG11201509189SA (da) |
| SI (1) | SI3012255T1 (da) |
| TW (1) | TWI639592B (da) |
| UA (1) | UA112626C2 (da) |
| WO (1) | WO2014203877A1 (da) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104395307A (zh) | 2013-06-17 | 2015-03-04 | 大鹏药品工业株式会社 | 地匹福林盐酸盐的稳定型晶体及其结晶化方法 |
| CN104744443A (zh) * | 2013-12-26 | 2015-07-01 | 江苏豪森药业股份有限公司 | 嘧啶二酮类化合物盐酸盐新晶型及其制备方法 |
| CN103788075B (zh) * | 2014-02-19 | 2018-03-27 | 齐鲁制药有限公司 | 一种胸苷磷酸化酶抑制剂的结晶形式及其制备方法 |
| CN104945385A (zh) * | 2014-03-31 | 2015-09-30 | 江苏豪森药业股份有限公司 | Tipracil盐酸盐的新晶型及其制备方法 |
| CN106018573B (zh) * | 2016-03-16 | 2018-09-18 | 江苏悦兴药业有限公司 | 一种tas-102中盐酸替比拉西的纯度检测方法 |
| CN105859691A (zh) * | 2016-04-07 | 2016-08-17 | 扬子江药业集团南京海陵药业有限公司 | 一种胸苷磷酸化酶抑制剂的新型结晶形式及其制备方法 |
| WO2018039359A1 (en) * | 2016-08-23 | 2018-03-01 | Board Of Regents, The University Of Texas System | Methods for the treatment of cancer-associated bone disease |
| WO2019002407A1 (en) * | 2017-06-28 | 2019-01-03 | Amneal Pharmaceuticals Company Gmbh | PROCESS FOR THE PREPARATION OF TIPIRACIL CHLORHYDRATE |
| CN107216314A (zh) * | 2017-08-02 | 2017-09-29 | 国药心制药有限公司 | 一种盐酸替匹嘧啶的晶型及其制备方法 |
| WO2019049174A1 (en) * | 2017-09-07 | 2019-03-14 | Msn Laboratories Private Limited, R&D Center | SOLID STATE FORMS OF 5-CHLORO-6 - [(2-IMINOPYRROLIDIN-1-YL) METHYL] PYRIMIDINE-2,4- (1H, 3H) -DIONE HYDROCHLORIDE AND METHODS OF PREPARATION THEREOF |
| WO2019053574A1 (en) * | 2017-09-14 | 2019-03-21 | Aurobindo Pharma Limited | PROCESS FOR THE PREPARATION OF CRYSTALLINE TIPIRACIL HYDROCHLORIDE |
| JP7330180B2 (ja) * | 2017-11-02 | 2023-08-21 | プロコス ソシエタ ペル アチオニ | チピラシル塩酸塩結晶ｉｉｉ型の製造方法 |
| US11730753B2 (en) | 2018-03-03 | 2023-08-22 | Natco Pharma Limited | Stable pharmaceutical compositions comprising trifluridine and tipiracil hydrochloride |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3088757B2 (ja) | 1995-03-29 | 2000-09-18 | 大鵬薬品工業株式会社 | ウラシル誘導体並びにそれを含有する抗腫瘍効果増強剤及び抗腫瘍剤 |
| EP0884051B1 (en) | 1996-09-24 | 2004-12-15 | Taiho Pharmaceutical Company Limited | Cancerous metastasis inhibitors containing uracil derivatives |
| JP4049477B2 (ja) | 1999-03-23 | 2008-02-20 | 大鵬薬品工業株式会社 | 副作用軽減剤 |
| JP4110347B2 (ja) | 1999-11-05 | 2008-07-02 | 大鵬薬品工業株式会社 | 抗ｈｉｖ剤 |
| US7799783B2 (en) * | 2005-01-26 | 2010-09-21 | Taiho Pharmaceutical Co., Ltd. | Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor |
| KR101390144B1 (ko) | 2006-04-13 | 2014-04-28 | 다이호야쿠힌고교 가부시키가이샤 | 염증성 장질환 치료제 |
| TWI426909B (zh) | 2006-06-30 | 2014-02-21 | Taiho Pharmaceutical Co Ltd | Radiation therapy enhancer |
| CN104395307A (zh) * | 2013-06-17 | 2015-03-04 | 大鹏药品工业株式会社 | 地匹福林盐酸盐的稳定型晶体及其结晶化方法 |
| CN103613877B (zh) * | 2013-11-20 | 2017-09-19 | 上海锦湖日丽塑料有限公司 | 适于吹塑成型的高耐热abs树脂组合物及其制备方法 |
| CN104744443A (zh) | 2013-12-26 | 2015-07-01 | 江苏豪森药业股份有限公司 | 嘧啶二酮类化合物盐酸盐新晶型及其制备方法 |
| CN103788075B (zh) * | 2014-02-19 | 2018-03-27 | 齐鲁制药有限公司 | 一种胸苷磷酸化酶抑制剂的结晶形式及其制备方法 |
| CN104945384B (zh) | 2014-03-25 | 2018-10-16 | 江苏豪森药业集团有限公司 | 5-氯-6-[(2-亚氨基-1-吡咯烷)甲基]-2,4(1h,3h)-嘧啶二酮或其盐的制备方法 |
| CN104945385A (zh) | 2014-03-31 | 2015-09-30 | 江苏豪森药业股份有限公司 | Tipracil盐酸盐的新晶型及其制备方法 |
| CN103980253B (zh) | 2014-05-06 | 2015-07-08 | 济南百诺医药科技开发有限公司 | 一种5-氯-6-(2-亚氨基吡咯烷基-1-基)甲基-2,4-(1h, 3h)嘧啶二酮盐酸盐的合成方法 |
-
2014
- 2014-06-17 CN CN201480000562.4A patent/CN104395307A/zh active Pending
- 2014-06-17 US US14/896,748 patent/US9527833B2/en active Active
- 2014-06-17 PT PT148143548T patent/PT3012255T/pt unknown
- 2014-06-17 JP JP2015522923A patent/JP6364409B2/ja active Active
- 2014-06-17 SI SI201431915T patent/SI3012255T1/sl unknown
- 2014-06-17 CN CN201910933531.9A patent/CN110746403A/zh active Pending
- 2014-06-17 NZ NZ714090A patent/NZ714090A/en unknown
- 2014-06-17 SG SG11201509189SA patent/SG11201509189SA/en unknown
- 2014-06-17 EP EP14814354.8A patent/EP3012255B1/en active Active
- 2014-06-17 ES ES14814354T patent/ES2898408T3/es active Active
- 2014-06-17 GE GEAP201414034A patent/GEP20186875B/en unknown
- 2014-06-17 EP EP17204730.0A patent/EP3305779A1/en active Pending
- 2014-06-17 RS RS20211505A patent/RS62691B1/sr unknown
- 2014-06-17 SG SG10201710916YA patent/SG10201710916YA/en unknown
- 2014-06-17 MX MX2015016986A patent/MX2015016986A/es active IP Right Grant
- 2014-06-17 RU RU2017124790A patent/RU2674441C1/ru active
- 2014-06-17 BR BR112015031619-0A patent/BR112015031619B1/pt active IP Right Grant
- 2014-06-17 DK DK14814354.8T patent/DK3012255T3/da active
- 2014-06-17 TW TW103120948A patent/TWI639592B/zh active
- 2014-06-17 PL PL14814354T patent/PL3012255T3/pl unknown
- 2014-06-17 CN CN201910111208.3A patent/CN109912573A/zh active Pending
- 2014-06-17 CN CN201610818347.6A patent/CN106967051A/zh active Pending
- 2014-06-17 MY MYPI2015002887A patent/MY173410A/en unknown
- 2014-06-17 RU RU2016100972A patent/RU2640417C2/ru active
- 2014-06-17 MA MA38668A patent/MA38668B2/fr unknown
- 2014-06-17 KR KR1020167001279A patent/KR101806346B1/ko active IP Right Grant
- 2014-06-17 CA CA2985006A patent/CA2985006C/en active Active
- 2014-06-17 UA UAA201600333A patent/UA112626C2/uk unknown
- 2014-06-17 HU HUE14814354A patent/HUE057352T2/hu unknown
- 2014-06-17 AU AU2014282281A patent/AU2014282281C1/en active Active
- 2014-06-17 CA CA2914999A patent/CA2914999C/en active Active
- 2014-06-17 GE GEAP201414225A patent/GEP20186841B/en unknown
- 2014-06-17 HR HRP20211903TT patent/HRP20211903T1/hr unknown
- 2014-06-17 LT LTEPPCT/JP2014/065985T patent/LT3012255T/lt unknown
- 2014-06-17 WO PCT/JP2014/065985 patent/WO2014203877A1/ja active Application Filing
- 2014-06-17 SG SG10202007643SA patent/SG10202007643SA/en unknown
- 2014-06-17 SG SG10201912293UA patent/SG10201912293UA/en unknown
-
2015
- 2015-04-10 HK HK15103542.0A patent/HK1203071A1/xx unknown
- 2015-12-17 PH PH12015502809A patent/PH12015502809A1/en unknown
-
2016
- 2016-11-16 US US15/352,858 patent/US10138223B2/en active Active
-
2018
- 2018-05-02 US US15/969,434 patent/US10457666B2/en active Active
- 2018-07-02 JP JP2018126102A patent/JP6526883B2/ja active Active
- 2018-08-20 AU AU2018219967A patent/AU2018219967C1/en active Active
-
2021
- 2021-12-07 CY CY20211101073T patent/CY1124868T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3012255T3 (da) | Stabil krystalform af tipiracilhydrochlorid og krystalliseringsfremgangsmåde dertil | |
| DK2958588T3 (da) | Kombination af vaccination og hæmning af PD-1-reaktionsvejen | |
| DK3080100T3 (da) | Hæmmere af lysinspecifik demethylase-1 | |
| HK1221224A1 (zh) | 依洛昔巴特的結晶修飾物 | |
| DK3067355T3 (da) | Krystaller af diazabicyclooctanderivat og fremgangsmåde til fremstilling af krystaller af diazabicyclooctanderivat | |
| DK3027618T3 (da) | Polymorf af syk-hæmmere | |
| DK2968208T3 (da) | Behandling af kataplexi | |
| DK3035802T3 (da) | Kontrolleret vækst af mikroorganismer | |
| DK3043785T3 (da) | Anvendelse af r-ketamin og salt deraf som lægemidler | |
| DK2961388T3 (da) | Kombinationer af lægemidler | |
| DK2919923T3 (da) | Holder-sortiment og rengøringsapparater til rengøring af åndedrætsapparater | |
| DK3087183T3 (da) | Modulation af angiopoietin-3-lignende ekspression | |
| DK2981541T3 (da) | Syntese og anvendelse af isotopmærkede glycaner | |
| DK3050883T3 (da) | Fremgangsmåde til fremstilling af diazabicyclooctanderivater og mellemprodukter | |
| DK2981255T3 (da) | Terapeutiske anvendelser af empagliflozin | |
| DK3021838T3 (da) | Behandling af fedme | |
| DK3328867T3 (da) | Krystallinsk form af fri base af lorlatinib | |
| DK3068954T3 (da) | Læanordning, bueformet element og anvendelse af læanordning | |
| DK3007695T3 (da) | Sammensætninger og fremgangsmåder til behandling af anæmi | |
| DK2955185T3 (da) | Polycycliske substituerede inhibitorer af pyrazol-kinaseaktivitet og anvendelse deraf | |
| DK2958978T3 (da) | Fremgangsmåde og anordning til fremstilling af brændstof ud af biomasse | |
| DK2996720T3 (da) | Stabile formuleringer af enkelte variable immunoglobulin-domæner og anvendelser deraf | |
| DK2988756T4 (da) | Formulering af kontraststof og dertil knyttet fremstillingsfremgangsmåde | |
| DK3205683T3 (da) | Sammensætninger og indretninger af poly-4-hydroxybutyrat | |
| DK2983695T3 (da) | Fremgangsmåder, anvendelser og sammensætninger af tie2- agonister |